89bio Presents Additional Exploratory Analyses from the Phase 1b/2a NASH Study

  New analysis of cohort 7 data using a three-reader pathologist panel showed that 6/19 patients scored as having fibrosis stage 4 at baseline (putative F4); excluding these patients resulted in higher histological response rates in the patients with F2-F3 fibrosis than previously reported -

https://www.marketscreener.com/quote/stock/89BIO-INC-74010954/news/89bio-Presents-Additional-Exploratory-Analyses-from-the-Phase-1b-2a-NASH-Study-of-Pegozafermin-at-AA-42214951/